Primacyt supports Transparency Agreement about Animal Research

Primacyt supports Transparency Agreement about Animal Research.

Primacyt has joined the Transparent Agreement about Animal Research. Leading German research companies such as Bayer, Merck, and Sanofi support this initiative. Dieter Runge, Managing Director of Primacyt, said, “As a leading producer of in vitro models for human and animal health and environmental safety, we actively contribute to reducing animal experiments. Our biological testing systems are important for replacing and reducing animal testing today and in the future.” The agreement is an initiative of the German Research Foundation (DFG, Deutsche Forschungsgemeinschaft) and the Alliance of Science Organizations in Germany.

Primacyt opens first foreign Office in China.

April 1, 2022. In cooperation with the GIC (German Industry & Commerce) China, the service unit of the AHK China, Primacyt Cell Culture Technology GmbH, will be represented by the GIC in the Chinese metropolis of Chengdu, Sichuan Province, starting from April 1st.

With about 20 million inhabitants, Chengdu is the capital of Sichuan province. As the most important city in Western China, Chengdu leads the so-called New Tier One Cities list and is one of China's most important economic centers after Shanghai, Shenzhen, Beijing, and Guangzhou.

Chengdu's hi-tech zone is among the most competitive biomedical, industrial areas. Therefore, we are pleased to have found a highly qualified employee in Ms. Rouxun Xiao, who will support our local sales partners, initiate new business relationships, and represent our company as Business Development Manager.

EUSAAT Congress in Linz, Austria

EUSAAT Congress in Linz, Austria. Primacyt Cell Culture Technology GmbH, March 28, 2022
The European Society for Alternatives to Animal Testing (EUSAAT) will hold its 36th Congress from 26th to 28th September 26 to 28 at the University of Linz, Austria. Leading 3R experts will meet and share their experiences on alternatives to animal use in life science. Topics focus on animal-free human-based cell culture, disease models, microphysiological systems, in vitro toxicology, biological barriers and efficacy and safety testing of medical devices, biopharmaceutics, drugs, cosmetics, and consumer products.
For further Information please use the link below.

Towards a reduced Pollution Society

Primacyt Cell Culture Technology GmbH, March 11, 2022

The Society of Environmental Toxicology and Chemistry (SETAC) Europe holds its 32nd Annual Meeting at the Bella Center Copenhagen from May 15 to May 19, 2022. The theme of this meeting is “Towards a reduce pollution society.” The topic reflects the European Green Deal, i.e., the Chemical Strategy for Sustainability, where chemicals are produced and used in a way that maximizes their contributions to society. The deadline for submission of late-breaking abstracts is Friday, March 25.
For further Information please use the link below.

Safety evaluation and risk assessment of pesticides using rainbow trout hepatocytes.

Primacyt Cell Culture Technology GmbH, February 16, 2022

Safety evaluation and risk assessment of pesticides using rainbow trout hepatocytes according to OECD guideline 319A.

In-depth risk assessment and safety evaluation are required for the registration of pesticides. The evaluation includes, but is not limited to, bioaccumulation factor studies in fish according to OECD guideline 305 (2012). To determine the bioconcentration factor, in vitro assays using hepatocytes and liver S9 fractions (OECD319A/B, 2018) are developed to support in silico testing and follow the 3 R principles. According to OECD guidelines, a recently published study from Bayer Crop Science has shown that fungicides penflufen and tebuconazole exhibit a similar metabolic behavior of in vitro hepatocyte assays using trout hepatocytes when compared with the in vivo data. The authors also compared the metabolism of these pesticides in trout hepatocytes (OECD 319A) and trout liver S9 fractions (OECD 319B). They showed that the metabolism of both compounds was faster in hepatocytes and revealed additional conjugates as transformation products. Therefore, they conclude that rainbow trout hepatocytes, although more expensive than the liver S9 fractions, should be the preferred model to cover the full metabolic capability of liver cells.

For further reading:
Tust M., Kohler M., Lagojda A, and Lamshoeft M: Comparison of the in vitro assays to investigate the hepatic metabolism of seven pesticides in Cyprinus carpio and Oncorhynchus mykiss.
The study can be accessed by the link below.

Liver Subcellular Fractions - New insights on in vitro biotransformation of anticoagulant rodenticides in fish.

Primacyt Cell Culture Technology GmbH February 12, 2022

The OECD 319B Rainbow Trout S9 assay bridges the gap between less robust in silico methods and the more relevant but time-consuming and more expensive in vivo assays. New insights on in vitro biotransformation of anticoagulant rodenticides in fish  J. Regnery. C. Riegraf, S.Jacob and A. Friesen. 

For environmental risk assessment, it is essential to evaluate the bioaccumulation potential of chemicals. So far, the bioaccumulation assessment is mainly based on fish bioconcentration factors (BCFs), with measured fish BCF data obtained under controlled laboratory conditions via aquatic or dietary exposure considered the most reliable information. However, while in support of the 3R initiative (replace, reduce, refine), animal testing is supposed to be minimized, other means like in silico approaches based on quantitative structure-activity relationship (QSAR) often do not account for the contribution of fish metabolism on intrinsic clearance of the chemical compounds. Thus, more recently, in vitro to in vivo extrapolation (IVIVE) methods were established to assess the bioaccumulation of chemicals in animals. Now scientists led by Julia Regnery of the Federal Institute of Hydrology in Koblenz and the German Environment Agency have published a study following the OECD test guideline 319B using liver subcellular S9 fraction to determine the in vitro biotransformation rate of biocidal and anticoagulants in rainbow trout (Oncorhynchus mykiss).

The study was published in Chemosphere and can be accessed by the link below.